The percentage of CD44+/CD24− cancer stem cell in bulk tumor of group 1 group is increased from a mean of 4.7% at baseline to 13.6% (p < 0.001) after 12 weeks of chemotherapy. The gene discussed is CD44; the disease is neoplasm.